| Effect of celecoxib on postoperative narcotic use and disease severity in patients with aspirin-exacerbated respiratory disease and chronic rhinosinusitis: a randomized controlled trial |
Ongoing |
Celecoxib |
4 |
114809 |
King Khalid University Hospital (Riyadh) King Abdulaziz University Hospital (Riyadh) |
| EASi-HF - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) >40% |
Ongoing |
BI 690517 , empagliflozin |
3 |
1378-0020 |
King Fahad Medical City (Riyadh), King Khalid University Hospital (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh) |
| Effect of Probiotics “Psychobiotics” on Depression in Adults with Obesity and Metabolic Syndrome in Riyadh City |
Ongoing |
Winclove’s Ecologic® Barrier probiotics |
3 |
E-23-7867 |
King Khalid University Hospital (Riyadh) |
| BalanceD-HF: A Phase III, Randomised, Double-blind Study to Evaluate the Effect of Balcinrenone/Dapagliflozin, Compared with Dapagliflozin, on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and Impaired Kidney Function |
Ongoing |
balcinrenone/dapagliflozin |
3 |
D6402C00012 |
King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Riyadh),King Fahad Medical City (Riyadh) ,King Khalid University Hospital (Riyadh) |
| Phase 3b, Open-label, Multicenter, Single-dose Study Investigating Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy Administered to Adult Subjects with Severe or Moderately Severe Hemophilia B with Detectable Pretreatment AAV5 Neutralizing Antibodies |
Ongoing |
HEMGENIX (etranacogene dezaparvovec) |
3b |
CSL222_3005 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease and Recurrent Vaso-occlusive Crises |
Completed |
Inclacumab |
3 |
GBT2104-132 |
Prince Mohammad Bin Naser Hospital, Jizan, Saudi Arabi |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Immunoglobulin A Nephropathy (IgAN) |
Ongoing |
Ravulizumab |
3 |
D928FC00001 |
King Faisal Specialist Hospital and Research Center (Riyadh),King Fahad Specialist Hospital (Dammam) |
| A Multicenter, Open-label, Single-arm, Phase 3 Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of BIIB059 (Litifilimab) in Adult Participants with Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus with or without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST LTE) |
Ongoing |
Litifilimab |
3 |
230LE305 |
King Faisal Specialist Hospital and Research Center (Riyadh), King Khalid University Hospital (Riyadh) |
| REAL-WORLD, LONG-TERM DATA COLLECTION TO GAIN CLINICAL INSIGHTS INTO ROCHE OPHTHALMOLOGY PRODUCTS (VOYAGER STUDY)- COMPLETE |
Ongoing |
Vabysmo |
4 |
MR41927 |
King Abdulaziz Medical City NG (Jeddah) |
| SODium BICarbonate for Metabolic Acidosis in the Intensive Care Unit (SODa-BIC): A multicentre, randomised, double-blind clinical trial |
Ongoing |
SODIUM BICARBONATE |
3 |
SCT23R/012/10 |
King Abdulaziz Medical City NG (Riyadh) |
